F-star bought out in $161M all-cash deal as Hong Kong's Sino Bio­pharm looks to­ward in­ter­na­tion­al ex­pan­sion

Af­ter more than a decade and a half of chart­ing its own course, F-star Ther­a­peu­tics will now set­tle un­der a new um­brel­la com­pa­ny.

The UK biotech will be ac­quired by in­voX Phar­ma, a sub­sidiary of Hong Kong’s Sino Bio­pharm, in a rough­ly $161 mil­lion all-cash deal, the com­pa­nies an­nounced Thurs­day morn­ing. F-star’s buy­out will val­ue its shares $FSTX at $7.12 apiece, near­ly an 80% pre­mi­um above Wednes­day’s clos­ing price.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER